NovoCure Limited is an oncology company. The Company is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields therapy is a treatment that uses electric fields tuned to specific frequencies to disrupt cancer cell division. TTFields therapy is delivered through a portable medical device. Optune is approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Optune Lua is approved by the FDA for the pathway for the treatment of malignant pleural mesothelioma (MPM) together with standard chemotherapies. It markets its products to United States, European Union, Germany, Japan and certain other countries.
|
|
|
|
|
Latest Earnings Missed Consensus (Q2 ending 06/2022) | Next Earnings Announcement | ||||||
---|---|---|---|---|---|---|---|
Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced July 28, 2022 | -$0.23 | Q2 Consensus of 8 analysts | -$0.15 | Difference from consensus | -58.62% | Q3 Earnings will announce | (Unconfirmed) October 28, 2022 |
Draw up to 3 lines inside the chart.
NVCR's fiscal year ends in December
Information provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.